Protara Therapeutics, Inc. - TARA Sotuvning sof marjinal rentabelligi

Protara Therapeutics Inc (TARA) - korporativ logo

Protara Therapeutics (TARA) uchun asosiy drayver klinik sinovlar doirasida TARA-002 dorisining rivojlanishidir. Kam uchraydigan kasalliklarga yo'naltirilgan strategiya ilmiy risklarni minimallashtiradi. Sof marja dinamikasi xarajatlar samaradorligini ko'rsatadi, bunda 0.00 ushbu parametr darajasini belgilaydi. Biroq, savdoning yo'qligi joriy ishlanmalarni moliyalashtirish uchun naqd pul rezervlarining asta-sekin kamayishiga olib kelmoqda.

Protara Tx (TARA) Sof foyda normasi: 04.07.2022 - 19.11.2026 davri uchun

Protara Therapeutics (TARA) - koʻrsatkichlar kesimi va moliyaviy hisobotlar

- aksiya narxi va baholash bo'yicha konsensus prognoz:
- emitentning bozor qiymati haqida ma'lumotlar:
Kompaniyaning fundamental baholanishi:Protara Therapeutics, Inc. - TARA
Protara Tx tayyor mahsulotlari

Barqarorlik omillarini aniqlash uchun investorlar barcha operatsion va soliq xarajatlari chegirib tashlanganidan keyin daromadning necha foizi sof foydaga aylanishini tushunishlari zarur. Oylik savdo marjasi tendentsiyasi ushbu samaradorlikni vizuallashtiradi, bu esa Protara Therapeutics (TARA) kompaniyasi TARA-002 terapiyasini kengaytirayotgan va onkologiya bozoriga tijorat kirishiga tayyorgarlik ko'rayotgan bir paytda juda muhimdir.

Protara Therapeutics kimlar bilan raqobatlashadi

ONC: Sotuvning sof marjinal rentabelligi|Sof marja Halozyme Inc. (HALO)|Sof marja RevMed|Sotuvning sof rentabelligi AAPG (Ascentage Pharma Group)|Sotuvning sof marjinal rentabelligi CGON|UroGen Pharma - Sotuvning sof rentabelligi|Bicara Therapeutics - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof marjinal rentabelligi Personalis Inc PSNL|Erasca Oncology - Sotuvning sof marjinal rentabelligi|Sof foyda normasi DCTH (Delcath Corp)|YMAB: Sotuvning sof marjinal rentabelligi|AURA - Kompaniya sotuv marjasi|CADL (Candel Therapeutics Inc.) - Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi ARAY (Accuray)|Sof foyda bo'yicha sotuv rentabelligi SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Sof marja|Sof marja Citius Oncology, Inc. CTOR|HURA - Sof foyda bo'yicha sotuv rentabelligi|FATE: Sof foyda bo'yicha sotuv rentabelligi|WHWK (aadibio.com) - Sotuvning sof rentabelligi|TCRX (TScan Therapeutics, Inc.) - Sof foyda bo'yicha sotuv rentabelligi|Sof marja Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Sotuvning sof marjinal rentabelligi|CVM (CEL-SCI Corporation) - Kompaniyaning sof rentabelligi|Sotuvning sof marjinal rentabelligi OSTX|Sotuvning sof marjinal rentabelligi Radiopharm Theranostics Ltd (RADX)|Sotuvning sof marjinal rentabelligi ARTV (Artiva Biotherapeutics)|Sotuvning sof marjinal rentabelligi Adlai Nortye Ltd. ANL|Veru Inc - Sotuvning sof marjinal rentabelligi|Kompaniya sotuv marjasi Tempest Therapeutics TPST|XLO: Sotuvning sof marjinal rentabelligi|Enochian BioSciences (RENB) - Sotuvning sof marjinal rentabelligi|Sof foyda bo'yicha sotuv rentabelligi MURA|Kairos Pharma Ltd - Sof foyda marjasi|Sotuvning sof marjinal rentabelligi OKUR|CytoMed Therapeutics Limited (GDTC) - Sof foyda bo'yicha marjinallik|Sotuvning sof marjinal rentabelligi CRIS (Curis, Inc.)|APLM: Sotuvning sof rentabelligi|Tharimmune Corporation - Sotuvning sof marjinal rentabelligi|ADVB: Sof marja|GNPX: Sotuvning sof marjinal rentabelligi|CLDI (Calidi Biotherapeutics Inc.) - Sof marja|Sof marja Sunshine Biopharma, Inc.|Sotuvning sof marjinal rentabelligi xeneticbio.com|Sof marja Salarius (SLRX)|Sof foyda bo'yicha sotuv rentabelligi Purple Biotech PPBT|Sof marja American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Sof marja|Checkpoint Therapeutics Inc. - Sotuvning sof marjinal rentabelligi|Sof foyda normasi ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Sof foyda bo'yicha sotuv rentabelligi|Ikena Oncology, Inc. - Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi NTBL|VIRX: Sof foyda normasi|Sof marja MorphoSys Corporation (MOR)|NAYA - Sof marja|Sotuvning sof marjinal rentabelligi AAPGV (Ascentage)